Stock Monitor: Evoke Pharma Post Earnings Reporting
LONDON, UK / ACCESSWIRE / December 12, 2017 / Active-Investors issued a free report on Akari Therapeutics, PLC (NASDAQ: AKTX), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symbol=AKTX as the Company's latest news hit the wire. On December 08, 2017, the New York based biopharmaceutical Company announced that the Phase-II COBALT trial, assessing the Company's lead candidate CoversinTM in patients with paroxysmal nocturnal hemoglobinuria (PNH) met the primary endpoint of a significant reduction in serum LDH (lactate dehydrogenase) to ≤1.8 times the upper limit of normal (ULN) by day 28. Sign up now for our free research reports at:
Active-Investors.com is currently working on the research report for Evoke Pharma, Inc. (NASDAQ: EVOK), which also belongs to the Healthcare sector as the Company Akari Therapeutics. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Akari Therapeutics most recent news is on our radar and we have decided to include it on our blog post. Today's free coverage is available at:
Progress of Phase-II COBALT Trial
Three additional patients were enrolled, together with the earlier five patients, into the COBALT, the Phase II 90-day, open label single arm clinical trial evaluating CoversinTM in patients with PNH who have never received a complement blocking therapy. The last three patients enrolled were treated with a revised dosing regimen of 45 mg every 24 hours. The median LDH value of the last three patients enrolled treated with higher 45mg dose, drop to 1.5 times the ULN at day 14 and below 1.5 times the ULN at day 28 and day 60, which was lower than the earlier patients on a 30mg dose who had a median LDH value of 2.2 times the ULN at day 28 and 1.7 times the ULN at day 60. No drug-related serious adverse events were observed.
Three of the six patients who were transfusion-dependent prior to the trial, did not require transfusions while on CoversinTM during the COBALT trial, and during the Company's long-term safety study, CONSERVE.
Akari to Progress into Phase-III Trials in Q1 2018 with Revised Dosing Regimen of 45 mg/day
Akari plans to commence two Phase-III PNH clinical trials with Coversin evaluating the revised dosing regimen of 45 mg in Q1 2018, as discussed with the US Food and Drug Administration (FDA) at a Type B End of Phase-II Meeting in September 2017.
CAPSTONE will assess the first Phase-III trial that will include treatment naïve patients. The second Phase-III trial, ASSET, is planned for the second half of 2018. The trial will include patients that switch from Alexion Pharmaceuticals' Soliris®. Soliris® is the first and only therapy approved for the treatment of patients with PNH to reduce hemolysis. Soliris® is approved for the treatment of patients with PNH in nearly 50 countries worldwide, including the United States, the European Union, and Japan.
What is Paroxysmal Nocturnal Hemoglobinuria?
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, chronic, debilitating disease of the blood characterized by destruction of red blood cells, blood clots, and impaired bone marrow function. PNH is primarily a disease of younger adults and usually continuous throughout the life of the patient. The disease results in the death of approximately 50% of affected individuals, and until recently, had no specific therapy.
CoversinTM, Akari's lead product candidate, is a recombinant small protein derived from a protein discovered in the saliva of the Ornithodoros moubata tick. CoversinTM is a second-generation and potentially best-in-class complement inhibitor, acts on complement component-C5, preventing release of C5a and formation of C5b–9. Akari's initial clinical targets for CoversinTM are PNH and atypical Hemolytic Uremic Syndrome.
About Akari Therapeutics, PLC
Founded in 2005, Akari Therapeutics is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically the complement system, the eicosanoid system, and the bioamine system for the treatment of rare and orphan diseases, in particular those where the complement system or leukotrienes or both complement and leukotrienes together play a primary role in disease progression.
Stock Performance Snapshot
December 11, 2017 - At Monday's closing bell, Akari Therapeutics' stock dropped 4.90%, ending the trading session at $4.66.
Volume traded for the day: 1.86 million shares, which was above the 3-month average volume of 520.54 thousand shares.
Stock performance in the last month – up 9.65%
After yesterday's close, Akari Therapeutics' market cap was at $69.25 million.
The stock is part of the Healthcare sector, categorized under the Drugs - Generic industry. This sector was up 0.3% at the end of the session.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.